Napsin B aspartic peptidase (pseudogene) (NAPSB)

Napsin B aspartic peptidase (NAPSB) is officially classified as a human pseudogene, meaning it is a non-functional remnant of a gene that no longer produces a functional protein. Current genome resources (NCBI, GeneCards) describe NAPSB as a pseudogene on chromosome 19, with no evidence of protein-coding function, biological activity, or direct involvement in human disease or therapy[3][5][6]. There is some mention in research of possible biomarker associations in cancer, but functional data and classical drug targeting roles are lacking. The related functional gene is NAPSA (Napsin A), which is an active aspartic protease involved in surfactant protein processing and frequently used as a diagnostic marker in lung adenocarcinoma[1][2]. NAPSB itself is not considered a valid molecular target and does not have a demonstrated role amenable to therapeutic modulation. Key context: - The confusion may arise from the similarity and close nomenclature to NAPSA, a bona fide enzyme and cancer biomarker. NAPSB is explicitly labeled a pseudogene and is not a protein, receptor, or enzyme in the classical sense[3][5][6]. - Therefore, any structured information relating to receptor/target functionality, disease roles, drug interactions, or mechanisms of action does not apply to NAPSB. Conclusion: The target provided, “napsin B aspartic peptidase (NAPSB),” is a pseudogene and not a functional receptor, enzyme, or druggable target. The functional counterpart is NAPSA, which is an active enzyme and diagnostic/prognostic marker in oncology[1][2][3][5][6].

Other names

NAP1LNAP2NAPBNAPSBP